| GTO ID | GTC3112 |
| Trial ID | NCT05456165 |
| Disease | Colorectal Carcinoma | Colonic Neoplasm |
| Therapy | mRNA vaccine |
| Treatment | GRT-C901;GRT-R902 |
| Co-treatment | Atezolizumab|Ipilimumab|Adjuvant chemotherapy |
| Phase | Phase2 |
| Recruitment status | Terminated |
| Title | A Randomized, Open-Label, Phase 2 Study of a Patient-Specific Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer With Minimal Residual Disease Following Surgical Resection and Standard Adjuvant Chemotherapy |
| Year | 2022 |
| Country | United States |
| Company sponsor | Gritstone bio, Inc. |
| Other ID(s) | GO-008|GRANITE-ADJUVANT |
| Vector information | |||
|
|||
| Cohort1: GRT-C901/GRT-R902 | |||||||||
|
|||||||||
| Cohort2: Adjuvant chemotherapy | |||||||||
|
|||||||||